Sintilimab
- Generic Name
- Sintilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2072873-06-2
- Unique Ingredient Identifier
- 8FU7FQ8UPK
- Associated Conditions
- -
- Associated Therapies
- -
Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2021-04-12
- Target Recruit Count
- 39
- Registration Number
- NCT04840758
Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 83
- Registration Number
- NCT04831710
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2021-03-22
- Target Recruit Count
- 49
- Registration Number
- NCT04809779
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2021-02-25
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04771715
- Locations
- 🇨🇳
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2021-02-25
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 40
- Registration Number
- NCT04769908
- Locations
- 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT04735861
- Locations
- 🇨🇳
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 100
- Registration Number
- NCT04728724
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
Exploratory Study of PD-1 Neoadjuvant Treatment of Recurrent Meningioma
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- Beijing Tiantan Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT04728568
- Locations
- 🇨🇳
Beijing TianTan Hospital, Beijing, Beijing, China
Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 48
- Registration Number
- NCT04724239
- Locations
- 🇨🇳
Cancer center of Sun Yat-sen University, Guangzhou, Guangdong, China
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 490
- Registration Number
- NCT04720716
- Locations
- 🇨🇳
Fudan Universtiy Zhongshan Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.